AU3508497A - Androgen receptor modulator compounds and methods - Google Patents
Androgen receptor modulator compounds and methodsInfo
- Publication number
- AU3508497A AU3508497A AU35084/97A AU3508497A AU3508497A AU 3508497 A AU3508497 A AU 3508497A AU 35084/97 A AU35084/97 A AU 35084/97A AU 3508497 A AU3508497 A AU 3508497A AU 3508497 A AU3508497 A AU 3508497A
- Authority
- AU
- Australia
- Prior art keywords
- compounds
- androgen receptor
- methods
- receptor modulator
- disclosed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 3
- 239000000849 selective androgen receptor modulator Substances 0.000 title abstract 2
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Electrotherapy Devices (AREA)
- Steroid Compounds (AREA)
Abstract
Non-steroidal compounds which are high affinity, high selectivity modulators for androgen receptors are disclosed. Also disclosed are pharmaceutical compositions incorporating such compounds, methods for employing the disclosed compounds and compositions for treating patients requiring androgen receptor agonsist, partial agonsit or antagonist therapy, intermediates useful in the preparation of the compounds and processes for the preparation of the androgen receptor modulator compounds.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2199796P | 1996-06-27 | 1996-06-27 | |
US60/021997 | 1996-06-27 | ||
PCT/US1997/011222 WO1997049709A1 (en) | 1996-06-27 | 1997-06-26 | Androgen receptor modulator compounds and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
AU3508497A true AU3508497A (en) | 1998-01-14 |
AU728178B2 AU728178B2 (en) | 2001-01-04 |
Family
ID=21807289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU35084/97A Ceased AU728178B2 (en) | 1996-06-27 | 1997-06-26 | Androgen receptor modulator compounds and methods |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0918774B9 (en) |
JP (1) | JP2000513362A (en) |
AT (1) | ATE209207T1 (en) |
AU (1) | AU728178B2 (en) |
BR (1) | BR9710988A (en) |
DE (1) | DE69709752T2 (en) |
DK (1) | DK0918774T3 (en) |
ES (1) | ES2168650T3 (en) |
NO (1) | NO311645B1 (en) |
PT (1) | PT918774E (en) |
RU (1) | RU2214412C2 (en) |
WO (1) | WO1997049709A1 (en) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6826407B1 (en) | 1999-03-29 | 2004-11-30 | Richard J. Helferich | System and method for integrating audio and visual messaging |
US7003304B1 (en) | 1997-09-19 | 2006-02-21 | Thompson Investment Group, Llc | Paging transceivers and methods for selectively retrieving messages |
US6636733B1 (en) | 1997-09-19 | 2003-10-21 | Thompson Trust | Wireless messaging method |
US6253061B1 (en) | 1997-09-19 | 2001-06-26 | Richard J. Helferich | Systems and methods for delivering information to a transmitting and receiving device |
US6983138B1 (en) | 1997-12-12 | 2006-01-03 | Richard J. Helferich | User interface for message access |
US6472415B1 (en) * | 1998-12-18 | 2002-10-29 | Biophysica, Inc. | Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes |
BR0013597A (en) | 1999-08-27 | 2002-07-16 | Ligand Pharm Inc | Androgen receptor modulating compounds and methods |
US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
AU6941200A (en) * | 1999-08-27 | 2001-03-26 | Ligand Pharmaceuticals Incorporated | 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators |
PE20010647A1 (en) | 1999-09-14 | 2001-06-23 | Lilly Co Eli | RETINOID X RECEPTOR MODULATORS (RXR) WITH IMPROVED PHARMACOLOGICAL PROFILE |
AU7736300A (en) | 1999-09-30 | 2001-04-30 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
AU2001230606A1 (en) * | 2000-02-10 | 2001-08-20 | Chugai Seiyaku Kabushiki Kaisha | Method of screening antiandrogen agent |
JP2004515462A (en) * | 2000-06-28 | 2004-05-27 | ブリストル−マイヤーズ スクイブ カンパニー | Fused cyclic compounds as modulators of nuclear hormone receptor function |
JP3908162B2 (en) | 2000-06-30 | 2007-04-25 | 中外製薬株式会社 | New antiandrogen |
EE200300108A (en) * | 2000-09-19 | 2005-02-15 | Bristol-Myers Squibb Company | Condensed heterocyclic succinimide compounds and their analogues as modulators of nuclear hormone receptor function |
US7214690B2 (en) | 2001-02-23 | 2007-05-08 | Ligand Pharmaceuticals Incorporated | Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods |
US7026484B2 (en) | 2001-02-23 | 2006-04-11 | Ligand Pharmaceuticals Incorporated | Tricyclic androgen receptor modulator compounds and methods |
ES2291507T3 (en) * | 2001-10-19 | 2008-03-01 | MERCK & CO., INC. | ANDROGEN RECEIVER MODULATORS AND PROCEDURES FOR THE SAME USE. |
CA2471754A1 (en) * | 2001-12-28 | 2003-07-17 | Takeda Chemical Industries, Ltd. | Androgen receptor antagonist |
KR101088352B1 (en) | 2002-02-28 | 2011-11-30 | 유니버시티 오브 테네시 리서치 파운데이션 | Multi-substituted selective androgen receptor modulators and methods of use thereof |
WO2003090672A2 (en) * | 2002-04-26 | 2003-11-06 | Ortho-Mcneil Pharmaceutical, Inc. | 2-(quinolonyl)-fused heterocycles as androgen receptor modulators |
US7405234B2 (en) | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
DE20301728U1 (en) | 2002-10-11 | 2004-03-11 | Ligand Pharmaceuticals, Inc., San Diego | 5-substituted-7,9-difluoro-5H-chromeno (3,4-f) quinoline compounds as selective progesterone receptor modulator compounds |
US7632858B2 (en) | 2002-11-15 | 2009-12-15 | Bristol-Myers Squibb Company | Open chain prolyl urea-related modulators of androgen receptor function |
EP1587804A1 (en) * | 2003-01-17 | 2005-10-26 | Warner-Lambert Company LLC | Androgen receptor antagonists |
CA2536349A1 (en) | 2003-08-22 | 2005-03-03 | Ligand Pharmaceuticals Incorporated | 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds |
US7256208B2 (en) | 2003-11-13 | 2007-08-14 | Bristol-Myers Squibb Company | Monocyclic N-Aryl hydantoin modulators of androgen receptor function |
US7820702B2 (en) | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
US7625923B2 (en) | 2004-03-04 | 2009-12-01 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
US7388027B2 (en) | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
WO2005090282A1 (en) | 2004-03-12 | 2005-09-29 | Ligand Pharmaceuticals Incorporated | Androgen receptor modulator compounds and methods |
AU2007212191B2 (en) * | 2006-02-10 | 2011-12-22 | Janssen Pharmaceutica N.V. | Novel imidazolopyrazole derivatives useful as selective androgen receptor modulators |
AU2009215843B2 (en) | 2008-02-22 | 2011-09-08 | Ellipses Pharma Ltd | Selective androgen receptor modulators |
US8268872B2 (en) | 2008-02-22 | 2012-09-18 | Radius Health, Inc. | Selective androgen receptor modulators |
EP2130831A1 (en) | 2008-06-06 | 2009-12-09 | InterMed Discovery GmbH | CDC25 inhibitors |
CN102414213B (en) * | 2009-04-30 | 2014-12-24 | 日产化学工业株式会社 | Novel crystal forms of tricyclic benzopyran compound and processes for producing same |
AU2011212813B2 (en) | 2010-02-04 | 2014-10-23 | Radius Health, Inc. | Selective androgen receptor modulators |
ME02474B (en) | 2010-05-12 | 2017-02-20 | Radius Health Inc | Therapeutic regimens |
US8642632B2 (en) | 2010-07-02 | 2014-02-04 | Radius Health, Inc. | Selective androgen receptor modulators |
US9133182B2 (en) | 2010-09-28 | 2015-09-15 | Radius Health, Inc. | Selective androgen receptor modulators |
CN103442737B (en) | 2011-01-20 | 2017-03-29 | 得克萨斯系统大学董事会 | MRI labellings, delivering and extraction system and its manufacture method and purposes |
US9421264B2 (en) | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
ES2939940T3 (en) | 2014-03-28 | 2023-04-28 | Univ Duke | Treatment of breast cancer using selective estrogen receptor modulators |
JP7221699B2 (en) | 2016-06-22 | 2023-02-14 | エリプセス ファーマ エルティーディー | AR+ methods of treating breast cancer |
CN106397317B (en) * | 2016-09-26 | 2019-03-22 | 天津师范大学 | 1,2,3,4- 3,4-tetrahydroquinoline compounds and its synthetic method and application |
CN106565723B (en) * | 2016-11-04 | 2019-08-27 | 江苏师范大学 | A kind of preparation method of furopyridine, benzo pyridines derivative compound |
FI3565542T3 (en) | 2017-01-05 | 2024-06-24 | Radius Pharmaceuticals Inc | Polymorphic forms of rad1901-2hcl |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69032648T2 (en) * | 1989-07-07 | 1999-04-08 | Endorecherche Inc., Ste-Foy, Quebec | Androgen derivatives to inhibit the activity of sex steroids |
US5677336A (en) * | 1993-10-21 | 1997-10-14 | Ligand Pharmaceuticals Incorporated | Non-steroid androgen receptor antagonist compounds and methods |
DK0800519T3 (en) * | 1994-12-22 | 2004-03-01 | Ligand Pharm Inc | Steroid receptor modulator compounds and methods |
-
1997
- 1997-06-26 ES ES97931460T patent/ES2168650T3/en not_active Expired - Lifetime
- 1997-06-26 AT AT97931460T patent/ATE209207T1/en not_active IP Right Cessation
- 1997-06-26 RU RU99101057/04A patent/RU2214412C2/en not_active IP Right Cessation
- 1997-06-26 PT PT97931460T patent/PT918774E/en unknown
- 1997-06-26 EP EP97931460A patent/EP0918774B9/en not_active Expired - Lifetime
- 1997-06-26 WO PCT/US1997/011222 patent/WO1997049709A1/en active IP Right Grant
- 1997-06-26 DE DE69709752T patent/DE69709752T2/en not_active Expired - Fee Related
- 1997-06-26 DK DK97931460T patent/DK0918774T3/en active
- 1997-06-26 JP JP10503562A patent/JP2000513362A/en not_active Ceased
- 1997-06-26 AU AU35084/97A patent/AU728178B2/en not_active Ceased
- 1997-06-26 BR BR9710988-6A patent/BR9710988A/en not_active IP Right Cessation
-
1998
- 1998-12-23 NO NO19986100A patent/NO311645B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO1997049709A1 (en) | 1997-12-31 |
NO986100D0 (en) | 1998-12-23 |
DE69709752D1 (en) | 2002-02-21 |
AU728178B2 (en) | 2001-01-04 |
DE69709752T2 (en) | 2002-07-18 |
JP2000513362A (en) | 2000-10-10 |
NO311645B1 (en) | 2001-12-27 |
PT918774E (en) | 2002-05-31 |
DK0918774T3 (en) | 2002-05-21 |
BR9710988A (en) | 2002-01-15 |
EP0918774A1 (en) | 1999-06-02 |
NO986100L (en) | 1998-12-23 |
RU2214412C2 (en) | 2003-10-20 |
EP0918774B9 (en) | 2002-04-10 |
ATE209207T1 (en) | 2001-12-15 |
ES2168650T3 (en) | 2002-06-16 |
EP0918774B1 (en) | 2001-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU3508497A (en) | Androgen receptor modulator compounds and methods | |
AU4597796A (en) | Steroid receptor modulator compounds and methods | |
MX9704640A (en) | Steroid receptor modulator compounds and methods. | |
WO2000066590A3 (en) | Tetracyclic progesterone receptor modulator compounds and methods | |
EP0911321A3 (en) | Compounds for the treatment of osteoporosis | |
EP0785793A4 (en) | Allosteric modulators of the nmda receptor | |
YU38801A (en) | Azabicycloalkanes as ccr5 modulators | |
AU7362496A (en) | Dimer-selective rxr modulators and methods for their use | |
PL331091A1 (en) | Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor | |
BG102726A (en) | Combined therapy for osteoporosis | |
WO1998058911A3 (en) | Prostaglandin agonists | |
AU9102198A (en) | Indole-3-carbinol, diindolylmethane and substituted analogs as antiestrogens | |
AU2536197A (en) | Tetrahydrobetacarboline compounds | |
AU7216498A (en) | Inhibitors of the urokinase receptor | |
MY127474A (en) | Naphthyl compounds, intermediates, compositions, and methods of use | |
AU1791497A (en) | At1 receptor antagonist for the stimulation of apoptosis | |
CA2259031A1 (en) | Androgen receptor modulator compounds and methods | |
AU2002243310A1 (en) | Isoindolyl and isoquinolinyl aroyl pyrrole compounds for the treatment of central nervous system disorders | |
AP9600780A0 (en) | Process for the preparation of peroxetine hydrochloride anhydrate and its use as therapeutic agent. |